London · Delayed Price · Currency is GBP · Price in EUR Valerio Therapeutics Société anonyme Company Description
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes.
The company develops developing VIO-01, which is in Phase 1/2 of the VIO-01 clinical study, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; and PlatON, generates DecoyTAC combining DNA decoy molecules capable of cell penetration with a linker+E3 ligand.
It also develops V-body platform, a bispecifics, ADCs, CAR-T, and V-body-oligonucleotide conjugates. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023.
The company is headquartered in Paris, France.
| Country | France |
| Founded | 1997 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 19 |
| CEO | Julien Miara |
Contact Details
Address: 49, boulevard du GEnEral Martial Valin Paris, 75015 France | |
| Phone | 33 1 45 58 76 00 |
| Website | valeriotx.com |
Stock Details
| Ticker Symbol | 0NWK |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Judith Greciet Ph.D., Pharmacy | Chief Executive Officer and Director |
| Nicolas Fellmann | Chief Financial Officer and Administrative and Finance Director |
| Dr. Françoise Bono Ph.D. | Chief Scientific Officer |
| Audrey Legentil-Dumery | Director of Human Resources |
| Michel Forest | Chief Pharmacist and Quality Assurance Director |
| Philippe M. Maitre | Chief of US Operations and Executive Vice President |
| Dr. Olivier de Beaumont M.D., MBA | Chief Medical Officer |